Background and objective: Accurate quantification of BCR-ABL mRNA is of critical
importance for managing chronic myeloid leukemia (CML) patients receiving Imatinib …

Optimal sample quality is a prerequisite to generate valid data in the detection of minimal
residual disease (MRD) in leukemias. Thus, the risk of obtaining 'false'-negative results is …

The sensitivity of assays designed to monitor minimal residual disease (MRD) by RT-PCR in
leukemia depend on quality and quantity of RNA derived from peripheral blood (PB) and …

Background: Optimum sample quality is a crucial requirement for molecular monitoring of
patients with chronic myeloid leukemia (CML) on therapy. Bedside RNA stabilization …

In a recent commentary, Faderl et al1 posed the question ''Should polymerase chain
reaction analysis to detect minimal residual disease in patients with chronic myelogenous …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

In the May 1, 1999 issue of Blood, Faderl et al1 discuss the possible clinical role of
polymerase chain reaction (PCR) analysis in the surveillance of residual disease in patients …

We used a recently developed system for real‐time quantitative polymerase chain reaction
(PCR) to determine residual disease in patients with chronic myeloid leukaemia. The …

Abstract Background and Objectives: Quantitation of BCR-ABL mRNA is emerging as the
standard of care to monitor the status of chronic myeloid leukemia (CML). Peripheral blood …

The focus of the study of minimal residual disease (MRD) is to redefine the concept of
remission by using more sensitive molecular techniques to detect level of disease burden …